Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less KRAS and More EGFR Mutations Compared to Advanced Adenocarcinomas
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25052959 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Jennie Petterson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, Sahlgrenska University Hospital, Västra Götalandsregionen, 413 45 Gothenburg, Sweden. Hauptthemen laut MEDLINE: Adenocarcinoma in Situ, Adenocarcinoma of Lung, Adenocarcinoma, Lung Neoplasms. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Strategic Fund from the Institute of Biomedicine, University of Gothenburg, the Swedish Cancer Foundation, ALF fund from the Sahlgrenska Academy Hospital in the Västra Götalandsre-gionen, Assar Gabrielsson's Foundation.
Abstract (Originalsprache)
Pulmonary adenocarcinoma (ADC) is a very diverse disease, both genetically and histologically, which displays extensive intratumor heterogeneity with numerous acquired mutations. ADC is the most common type of lung cancer and is believed to arise from adenocarcinoma in situ (AIS) which then progresses to minimally invasive adenocarcinoma (MIA). In patients of European ethnicity, we analyzed genetic mutations in AIS (n = 10) and MIA (n = 18) and compared the number of genetic mutations with advanced ADC (n = 2419). Using next-generation sequencing, the number of different mutations detected in both AIS (87.5%) and MIA (94.5%) were higher (p < 0.001) than in advanced ADC (53.7%). In contrast to the high number of mutations in Kirsten rat sarcoma virus gene (KRAS) in advanced ADC (34.6%), there was only one case of AIS with KRAS G12C mutation (3.5%; p < 0.001) and no cases of MIA with KRAS mutation (p < 0.001). In contrast to the modest prevalence of epidermal growth factor receptor (EGFR) mutations in advanced ADC (15.0%), the fraction of EGFR mutant cases was higher in both in AIS (22.2%) and MIA (59.5%; p < 0.001). The EGFR exon 19 deletion mutation was more common in both MIA (50%; n = 6/12) and ADC (41%; n = 149/363), whereas p.L858R was more prevalent in AIS (75%; n = 3/4). In contrast to pulmonary advanced ADC, KRAS driver mutations are less common, whereas mutations in EGFR are more common, in detectable AIS and MIA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pathology, Sahlgrenska University Hospital, Västra Götalandsregionen, 413 45 Gothenburg, Sweden.
- Department of Medical Chemistry and Cell Biology, Institute of Biomedicine, University of Gothenburg, Sahlgrenska Academy, 405 30 Gothenburg, Sweden.
- Sahlgrenska Center for Cancer Research, University of Gothenburg, Gothenburg, Sahlgrenska Academy, 405 30 Gothenburg, Sweden.
- Department of Clinical Oncology, Sahlgrenska University Hospital, Västra Götalandsregionen, 413 45 Gothenburg, Sweden.
- Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, 413 45 Gothenburg, Sweden.
- Wallenberg Centre for Molecular and Translational Medicine, University of Gothenburg, 413 45 Gothenburg, Sweden.
ORCID-Profile: Ella Äng Eklund, Andreas Hallqvist, Volkan I Sayin, Levent M Akyürek
Förderung
- Strategic Fund from the Institute of Biomedicine, University of Gothenburg, the Swedish Cancer Foundation
- ALF fund from the Sahlgrenska Academy Hospital in the Västra Götalandsre-gionen
- Assar Gabrielsson's Foundation
- Adlerbertska Forskningsstiftelsen
- Strategic Fund from the Institute of Biomedicine, the University of Gothenburg, the Swedish Cancer Foundation
- ALF fund
- Assar Gabrielsson’s Foundation
Zitieren
APA
Petterson, J., Mustafa, D., Bandaru, S., Eklund, E. Ä., Hallqvist, A., Sayin, V. I., Gagné, A., Fagman, H., & Akyürek, L. M. (2024). Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less KRAS and More EGFR Mutations Compared to Advanced Adenocarcinomas. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052959
Vancouver
Petterson J, Mustafa D, Bandaru S, Eklund EÄ, Hallqvist A, Sayin VI, et al. Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less KRAS and More EGFR Mutations Compared to Advanced Adenocarcinomas. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25052959
BibTeX
@article{Petterson2024,
author = {Petterson, Jennie and Mustafa, Dyar and Bandaru, Sashidar and Eklund, Ella Äng and Hallqvist, Andreas and Sayin, Volkan I and Gagné, Andréanne and Fagman, Henrik and Akyürek, Levent M},
title = {Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less KRAS and More EGFR Mutations Compared to Advanced Adenocarcinomas},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25052959}
}
EUVIMED